Recurrent Breast Cancer Completed Phase 2 Trials for Bortezomib (DB00188)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00025584PS-341 in Treating Women With Metastatic Breast CancerTreatment